Sponsors (4)
The bill coordinates and funds standards, tools, and security guidance to make nucleic-acid screening more reliable and harder to misuse, while imposing compliance costs and creating a federal-centered consensus process that may advantage larger, well-funded actors and requires modest new federal spending.
Researchers, biotech firms, and clinical labs gain funded standards, measurement tools, and validation resources to improve the accuracy and reliability of nucleic-acid screening and related assays, making tests more trustworthy and reproducible.
Improves operational security and access-control guidance for synthetic nucleic acids and AI-enabled design tools, reducing the risk of accidental or deliberate misuse.
Creates an industry–academia–nonprofit consortium to develop consensus best practices and roadmaps, aligning stakeholders, reducing fragmentation, and providing clearer adoption pathways for standards.
Small biotech companies, suppliers, and some labs face new compliance expectations that could raise operational costs and create barriers to market entry.
Federal-directed consensus processes and standards-setting may privilege well-resourced incumbents and domestic actors, disadvantaging smaller or international competitors and limiting diversity of approaches.
Authorizes roughly $25 million (FY2026–2030), increasing federal spending and potentially diverting NIST or other resources from other research priorities.
Based on analysis of 2 sections of legislative text.
Authorizes NIST to research and develop measurement-based biosecurity best practices and technical standards for nucleic acid synthesis screening, including AI risks, and to convene a public-private consortium.
Directs NIST to develop and support technical standards, best practices, and measurement research for biosecurity in nucleic acid synthesis screening, including AI-related risks, and to convene a public-private consortium to set priorities and deliver a report to Congress. Authorizes $5 million per year for FY2026–FY2030 from NIST research funds to carry out the work. Requires the NIST Director, working with other federal agencies and stakeholders, to research testing accuracy, operational security, access controls, conformity assessment, and evaluation methods for nucleic acid synthesis screening, and to produce consensus roadmaps and guidance within 18 months after the consortium's first meeting.
Official title: To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Introduced April 28, 2025 by Andrea Salinas · Last progress July 21, 2026